Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT-N2: Naltrexone Neuroimaging in Eating Disorders
NCT04935931Phase 1Completed
- Sponsor
- Children's Mercy Kansas City
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naltrexone in eating disorders, sponsored by Children's Mercy Kansas City. Primary endpoints: Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Nucleus Accumbens and Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Dorsal Anterior Cingulate Cortex. Started Jul 2021; status: completed.
02
Drugs
naltrexone
03
Conditions
eating disorders
Beyond the preview
Go deeper on NCT04935931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935931.